NENatonalinsutute forHealth and Care ExcellenceNICE贝guidanceTrastuzumab deruxtecanfor treating HER2-positiveunresectable or metastaticbreast cancer after 1 ormore anti-HER2treatme...
NENatonalinsutute forHealth and Care ExcellenceNICE贝guidancePolatuzumab vedotin incombination for untreateddiffuse large B-celllymphomaTechnology appraisal guidancePublished:1 Mar...
NENatonalinsutute forHealth and Care ExcellenceNICE贝guidancePembrolizumab pluschemotherapy with orwithout bevacizumab forpersistent,recurrent ormetastatic cervical cancerTechnolog...
NENatonalinsutute forHealth and Care ExcellenceNICE贝guidanceNivolumab withfluoropyrimidine-andplatinum-basedchemotherapy foruntreated unresectableadvanced,recurrent,ormetastatic o...
NCE Naonaltitute forHealth and Care ExcellenceNICE贝guidanceNivolumab with platinum-and fluoropyrimidine-based chemotherapy foruntreated HER2-negativeadvanced gastric,gastro-oesoph...
NENational nstitute forHealth and Care ExcellenceNICE贝guidanceOlaparib for previouslytreated BRCA mutation-positive hormone-relapsedmetastatic prostate cancerTechnology appraisal ...
NCENaional nstitute forHealth and Care ExcellenceNICE贝guidanceEptinezumab forpreventing migraineTechnology appraisal guidancePublished:1 March 2023www.nice.org.uk/quidance/ta871NI...
NCENational nstitute forHealth and Care ExcellenceNICE贝guidanceOlaparib for adjuvanttreatment of BRCAmutation-positiveHER2-negative high-riskearly breast cancer afterchemotherapyT...
医知素材库![2023NICE技术鉴定指导意见：曲妥珠单抗deruxtecan用于在1次或多次抗HER2治疗后治疗HER2阳性不可切除或转移性乳腺癌[TA862]-医知素材库](https://cdn.jiaoyuwz.com/2023NICE技术鉴定指导意见：曲妥珠单抗deruxtecan用于在1次或多次抗HER2治疗后治疗HER2阳性不可切除或转移性乳腺癌[TA862]-816b7b06b5-pdf-1.webp)
![2023NICE技术鉴定指导意见：泊洛妥珠单抗-维布妥昔单抗联合治疗未经治疗的弥漫性大B细胞淋巴瘤[TA874]-医知素材库](https://cdn.jiaoyuwz.com/2023NICE技术鉴定指导意见：泊洛妥珠单抗-维布妥昔单抗联合治疗未经治疗的弥漫性大B细胞淋巴瘤[TA874]-7a4a756b81-pdf-1.webp)
![2023NICE技术鉴定指导意见：纳武单抗联合化疗用于可切除非小细胞肺癌的新辅助治疗[TA876]-医知素材库](https://cdn.jiaoyuwz.com/2023NICE技术鉴定指导意见：纳武单抗联合化疗用于可切除非小细胞肺癌的新辅助治疗[TA876]-d0b06576c7-pdf-1.webp)
![2023NICE技术鉴定指导意见：派姆单抗联合化疗联合或不联合贝伐单抗治疗持续性、复发性或转移性宫颈癌[TA885]-医知素材库](https://cdn.jiaoyuwz.com/2023NICE技术鉴定指导意见：派姆单抗联合化疗联合或不联合贝伐单抗治疗持续性、复发性或转移性宫颈癌[TA885]-b59502e641-pdf-1.webp)
![2023NICE技术鉴定指导意见：纳武单抗联合铂类和氟嘧啶类化疗治疗未经治疗的HER2阴性晚期胃癌、胃食管交界处癌或食管腺癌[TA857]-医知素材库](https://cdn.jiaoyuwz.com/2023NICE技术鉴定指导意见：纳武单抗联合铂类和氟嘧啶类化疗治疗未经治疗的HER2阴性晚期胃癌、胃食管交界处癌或食管腺癌[TA857]-a0a6541175-pdf-1.webp)
![2023NICE技术鉴定指导意见：乐伐替尼联合派姆单抗治疗未经治疗的晚期肾细胞癌[TA858]-医知素材库](https://cdn.jiaoyuwz.com/2023NICE技术鉴定指导意见：乐伐替尼联合派姆单抗治疗未经治疗的晚期肾细胞癌[TA858]-ad7f1cbb23-pdf-1.webp)
![2023NICE技术鉴定指导意见：奥拉帕尼用于既往治疗过的BRCA突变阳性激素复发转移性前列腺癌[TA887]-医知素材库](https://cdn.jiaoyuwz.com/2023NICE技术鉴定指导意见：奥拉帕尼用于既往治疗过的BRCA突变阳性激素复发转移性前列腺癌[TA887]-15c6a9fc69-pdf-1.webp)
![2023NICE技术鉴定指导意见：艾普奈珠单抗预防偏头痛[TA871]-医知素材库](https://cdn.jiaoyuwz.com/2023NICE技术鉴定指导意见：艾普奈珠单抗预防偏头痛[TA871]-165ea969c7-pdf-1.webp)
![2023NICE技术鉴定指导意见：奥拉帕尼辅助治疗BRCA突变阳性HER2阴性高危早期乳腺癌化疗后[TA886]-医知素材库](https://cdn.jiaoyuwz.com/2023NICE技术鉴定指导意见：奥拉帕尼辅助治疗BRCA突变阳性HER2阴性高危早期乳腺癌化疗后[TA886]-fdf398d47d-pdf-1.webp)
